Literature DB >> 22173716

A prospective analysis of patient outcome following treatment of T3 rectal cancer with neo-adjuvant chemoradiotherapy and transanal excision.

Rory P Kennelly1, Anna Heeney, Anne White, David Fennelly, Kieran Sheahan, John M P Hyland, P Ronan O'Connell, Desmond C Winter.   

Abstract

BACKGROUND: Local excision is an alternative to anterior or abdomino-perineal resection in patients with early rectal cancer. In more advanced disease, neo-adjuvant therapy (CRXT) can result in significant disease regression such that local excision may be considered. The primary aim was to assess oncological outcome in patients with T3 rectal cancer treated with CRXT and local excision due to unsuitability for or aversion to anterior resection and stoma. The secondary aim was to examine oncological outcomes in patients treated in a similar way in the published literature.
METHODS: Between July 2006 and July 2009, patients with rectal cancer staged T3, N0/N1, M0 who were deemed unfit for or who refused anterior resection were offered long-course CRXT. Patients were restaged 8 weeks following completion. If there was a good response (regression grade 2 or 3 clinically and radiologically), full thickness transanal excision was performed. All patients were followed regularly (monthly CT abdomen/pelvis and annual endoscopy) to assess for recurrence of disease. A literature search of PubMed was performed to identify all prospective data available of T3 rectal cancers managed with CRXT and local excision.
RESULTS: Ten patients were treated over 3 years. Six patients had complete pathological response, while four patients had a partial response. The resection margins following local excision were clear in all. There was no local recurrence (median follow-up 24 months, range 9-42 months).
CONCLUSION: Neo-adjuvant chemoradiotherapy and local excision is an option in patients unfit for or averse to major surgical resection if there is a good response to CRXT.

Entities:  

Mesh:

Year:  2011        PMID: 22173716     DOI: 10.1007/s00384-011-1388-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  24 in total

Review 1.  Stoma complications: a literature overview.

Authors:  J Shabbir; D C Britton
Journal:  Colorectal Dis       Date:  2010-10       Impact factor: 3.788

2.  Management of anastomotic leakage after nondiverted large bowel resection.

Authors:  A Alves; Y Panis; M Pocard; J M Regimbeau; P Valleur
Journal:  J Am Coll Surg       Date:  1999-12       Impact factor: 6.113

3.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

Review 4.  Rectum-conserving surgery in the era of chemoradiotherapy.

Authors:  F M Smith; D Waldron; D C Winter
Journal:  Br J Surg       Date:  2010-12       Impact factor: 6.939

5.  Endoscopic posterior mesorectal resection after transanal local excision of T1 carcinomas of the lower third of the rectum.

Authors:  Andreas Zerz; Beat P Müller-Stich; Joachim Beck; Georg R Linke; Ignatio Tarantino; Jochen Lange
Journal:  Dis Colon Rectum       Date:  2006-06       Impact factor: 4.585

6.  Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997.

Authors:  R J Heald; B J Moran; R D Ryall; R Sexton; J K MacFarlane
Journal:  Arch Surg       Date:  1998-08

7.  cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.

Authors:  José G Guillem; Juan A Díaz-González; Bruce D Minsky; Vincenzo Valentini; Seung-Yong Jeong; Miguel A Rodriguez-Bigas; Claudio Coco; Rebecca Leon; José L Hernandez-Lizoain; José J Aristu; Elyn R Riedel; Donato Nitti; W Douglas Wong; Salvatore Pucciarelli
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

Review 8.  Local therapy for rectal cancer: still controversial?

Authors:  F Bretagnol; E Rullier; B George; B F Warren; N J Mortensen
Journal:  Dis Colon Rectum       Date:  2007-04       Impact factor: 4.585

9.  Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience.

Authors:  Vassiliki L Tsikitis; David W Larson; Venkat P Poola; Heidi Nelson; Bruce G Wolff; John H Pemberton; Robert R Cima
Journal:  J Am Coll Surg       Date:  2009-05-28       Impact factor: 6.113

10.  Absence of lymph nodes in the resected specimen after radical surgery for distal rectal cancer and neoadjuvant chemoradiation therapy: what does it mean?

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Viviane Rawet; Diego D Pereira; Afonso H S Sousa; Desiderio Kiss; Ivan Cecconello
Journal:  Dis Colon Rectum       Date:  2008-03       Impact factor: 4.585

View more
  8 in total

1.  Development and validation of an MRI-based radiomic nomogram to distinguish between good and poor responders in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.

Authors:  Jia Wang; Xuejun Liu; Bin Hu; Yuanxiang Gao; Jingjing Chen; Jie Li
Journal:  Abdom Radiol (NY)       Date:  2020-11-05

2.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

3.  Tumor stage in patients operated for rectal cancer: a comparison of the pre-operative MR and the resection specimen, with specific attention to the effect of neo-adjuvant radiotherapy.

Authors:  Elmer E van Eeghen; Sandra D Bakker; Gerwin Fransen; Marcel J Flens; Ruud J L F Loffeld
Journal:  J Gastrointest Oncol       Date:  2017-08

4.  Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy.

Authors:  Lin Xiao; Xin Yu; Wenjing Deng; Huixia Feng; Hui Chang; Weiwei Xiao; Huizhong Zhang; Shaoyan Xi; Mengzhong Liu; Yujia Zhu; Yuanhong Gao
Journal:  Sci Rep       Date:  2016-10-10       Impact factor: 4.379

Review 5.  Current debate in the oncologic management of rectal cancer.

Authors:  Trish Millard; Paul R Kunk; Erika Ramsdale; Osama E Rahma
Journal:  World J Gastrointest Oncol       Date:  2016-10-15

6.  Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.

Authors:  B Creavin; E Ryan; S T Martin; A Hanly; P R O'Connell; K Sheahan; D C Winter
Journal:  Br J Cancer       Date:  2016-12-20       Impact factor: 7.640

7.  Multimodal Assessments Are Needed for Restaging after Neoadjunvant Chemoradiation Therapy in Rectal Cancer Patients.

Authors:  Bong-Hyeon Kye; Hyung-Jin Kim; Gun Kim; Jun-Gi Kim; Hyeon-Min Cho
Journal:  Cancer Res Treat       Date:  2015-08-10       Impact factor: 4.679

8.  A multicentre cohort study assessing the utility of routine blood tests as adjuncts to identify complete responders in rectal cancer following neoadjuvant chemoradiotherapy.

Authors: 
Journal:  Int J Colorectal Dis       Date:  2022-03-24       Impact factor: 2.796

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.